Evaluation of outcomes of calcitonin gene-related peptide (CGRP)-targeting therapies for acute and preventive migraine treatment based on patient sex.
Frank PorrecaEdita NavratilovaJoe HirmanAntoinette Maassen van den BrinkRichard B LiptonDavid W DodickPublished in: Cephalalgia : an international journal of headache (2024)
Small molecule CGRP-R antagonists are effective in acute migraine therapy in women but available data do not demonstrate effectiveness in men. CGRP-targeting therapies are effective for migraine prevention in both male and female episodic migraine patients but possible sex differences remain uncertain. In male and female chronic migraine patients, CGRP/CGRP-R antibodies were similarly effective. The data highlight possible differential effects of CGRP targeted therapies in different patient populations and the need for increased understanding of CGRP neurobiology in men and women.
Keyphrases
- end stage renal disease
- small molecule
- ejection fraction
- newly diagnosed
- chronic kidney disease
- liver failure
- randomized controlled trial
- prognostic factors
- systematic review
- case report
- peritoneal dialysis
- stem cells
- gene expression
- drug induced
- big data
- electronic health record
- machine learning
- mesenchymal stem cells
- respiratory failure
- cancer therapy
- pregnant women
- copy number
- bone marrow
- hepatitis b virus
- transcription factor
- genome wide
- middle aged
- deep learning
- smoking cessation